Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes

  • US 6,063,772 A
  • Filed: 06/15/1998
  • Issued: 05/16/2000
  • Est. Priority Date: 01/23/1996
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of treating a disease responsive to ribavirin, comprising:

  • recognizing progression of the disease as being mediated at least in part by Th1 lymphocytes;

    recognizing ribavirin as being effective to promote a Th1 response and suppress a Th2 response when administered in a dosage range below which both Th1 and Th2 responses are suppressed; and

    administering ribavirin to a patient having the disease within the dosage range.

View all claims

    Thank you for your feedback